Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Narrative) (Details)

v3.22.0.1
Significant Transactions (Narrative) (Details)
 3 Months Ended 6 Months Ended
Nov. 01, 2021
USD ($)
ft²
$ / shares
shares
Aug. 23, 2021
USD ($)
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Stock purchase agreement, value of shares to be purchased       $ 2,500,000 $ 0
Purchase price allocated   $ 7,500,000      
College Station Investors LLC And Bryan Capital [Member]          
Area of facility | ft² 130,000        
Total purchase price $ 28,750,000        
Cash payment $ 28,000,000        
Percentage of base rent 6.50%        
Fair market value of property $ 151,450        
Cash consideration for equity interest acquired $ 50,000        
Number of warrants issued | shares 1,289,581        
Warrants, exercise price per share | $ / shares $ 1.33        
Shares issued under the Warrant | shares 289,581        
Fair value of the warrant $ 217,255        
College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan          
Secured term loan $ 22,375,000        
Interest rate (as percent) 3.25%        
Unrestricted cash $ 10,000,000        
Irrevocable letter of credit 5,469,000        
Cost incurred to attain debt $ 322,000        
Interest expense     $ 123,000 123,000  
College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock          
Warrants issuable | shares 1        
Percentage of equity interest 0.01%        
Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, notice duration to terminate contract   30 days      
Purchase price allocated   $ 7,500,000      
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, royalty payment term   10 years      
Collaboration and license agreement, period to cure breach of contract   60 days      
Collaboration and license agreement, notice duration to terminate contract   90 days      
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, period to cure breach of contract   30 days      
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member]          
Milestone payments   $ 15,000,000      
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, period to cure breach of contract   60 days      
Collaboration and license agreement, agreement term   5 years      
Collaboration and license agreement, notice duration to terminate contract   90 days      
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, period to cure breach of contract   30 days      
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Financing Requirement not Met [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, notice duration to terminate contract   30 days      
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member]          
Milestone payments   $ 15,000,000      
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Theraputics, Inc. [Member]          
Collaboration and license agreement, royalty payment term   10 years      
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]          
Stock purchase agreement, number of shares purchased | shares   1,909,563      
Stock purchase agreement, value of shares purchased   $ 5,000,000      
Stock purchase agreement, number of shares to be purchased | shares   954,782      
Stock purchase agreement, value of shares to be purchased   $ 2,500,000   2,500,000  
Preferential dividend rate percentage   8.00%      
Minimum required shares to be eligible for preferential dividend rate | shares   1,500,000      
Proceeds from conversion of preferred stock to common stock   $ 30,000,000      
Liability for the assumed acquisition     $ 2,500,000 $ 2,500,000